Eli Lilly’s Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief

Key Points Retatrutide’s recent trial results suggest it may be even better than Eli Lilly’s already approved GLP-1 medication, tirzepatide. Besides weight loss, retatrutide helped many people with osteoarthritis in their knees feel completely pain-free by the end of the study. GLP-1 products have been huge catalysts for Eli Lilly’s growth in recent quarters, and […]

Mission Foods: NEW YEAR, NEW NUTRITION PLAN!

From GLP-1 to Keto, hear the nutrition tips and recipes you need to stay on track in the New Year IRVING, Texas, Jan. 14, 2026 /PRNewswire/ — BACKGROUND: As the calendar turns from December to January, millions of Americans vow that this will be the year they stick to their New Year’s…

Day 2 @ JP Morgan in Obesity Drugs and Therapies

Here are the **highlights from Day 2 of the JP Morgan Healthcare Conference (San Francisco) specifically related to obesity, weight-gain therapies, and related drug developments Fierce PharmaPharmaceutical TechnologyReutersFierce BiotechPharmaceutical Technology 🧪 New & Emerging TherapiesAmgen’s MariTide weight-loss programAmgen touted positive data on its experimental obesity drug MariTide, showing the therapy helped trial participants maintain significant […]

Day 1 @ JP Morgan in Obesity Drugs and Therapies

JP Morgan 2026: Obesity & GLP-1 Therapies Take Center StageWhat the Latest Deals and Data Mean for the Future of Metabolic MedicineThe J.P. Morgan Healthcare Conference once again served as the bellwether for where biotech and pharma are headed—and in 2026, GLP-1 and obesity therapeutics dominated the conversation.From next-generation incretin drugs to RNA-based obesity targets […]

Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety

by Ariana M. Chao, Adam Gilden, Thomas A. Wadden Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care. However, rising use brings concerns about side effects, long-term outcomes, and unregulated products. Ensuring safe access requires oversight, monitoring, and coordinated clinical care. In this Perspective, Ariana Chao, Adam Gilden and Thomas Wadden […]